Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2020 Vision For FDA's Sentinel: 'Systemic' Integration Of Surveillance Looms

Executive Summary

PDUFA reauthorization agreement sets up fiscal 2020 as milestone for weaving active surveillance into drug review – and for keeping sponsors informed of activities that affect their products.

Advertisement

Related Content

US FDA Gains Budget Increase In FY 2017… And Not Through Fees
Woodcock's Legacy: CDER Organizational Improvements
PDUFA VI: A Machine To Speed R&D Time, Cut Costs
PDUFA's 'Real-World' Journey Expected To Be Slow Walk
Sentinel’s “IMPACT” Beyond Safety: Anti-Coagulant Study Is Early Test
Reality Check For Real World Data: FDA’s Sentinel Network Enters “Production” Stage

Topics

Advertisement
UsernamePublicRestriction

Register

PS118844

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel